Q-omics provides the consensus-scored PARK7P2 profile across patient tissues and cancer cell-line models. PARK7P2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, PARK7P2 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, PARK7P2 RNA expression shows 11,203 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUSC, and LSCC as cancer lineages where PARK7P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PARK7P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PARK7P2 survival associations across molecular data types. PARK7P2 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PARK7P2 RNA expression–survival associations across cancer types. High PARK7P2 expression shows unfavorable associations in HNSC, ACC, UVM and BRCA, but favorable associations in LUSC and UCS. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify LUSC as the clearest survival context for PARK7P2 RNA expression.
This table summarizes PARK7P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for PARK7P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PARK7P2 shows higher tumor expression in LUSC, BRCA, HNSC, COAD and STAD. The LUSC box plot shows higher PARK7P2 RNA expression in tumor versus normal tissue (log2 FC = +0.169, t-test p = .003).
This table shows molecular features associated with PARK7P2 in patient tissues and cancer cell lines. In patient samples, PARK7P2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
